300006 Chongqing Lummy Pharmaceutical
- 2.76
- +0.07+2.60%
Chongqing Lummy Pharmaceutical News
Laimei Pharmaceutical (300006.SZ): Net loss of 4.575,300 yuan in the first quarter
On April 23, Ge Longhui Pharmaceutical (300006.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 181 million yuan, a year-on-year decrease of 20.09%; net profit attributable to shareholders of listed companies - 4,5753 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 7.4337 million yuan; basic earnings per share - 0.0043 yuan.
Lemei Pharmaceutical (300006.SZ): Currently, tadalafil tablets sold as agents by the company account for a small share of revenue
Gelonghui, April 18 | Lemei Pharmaceutical (300006.SZ) said on the investor interactive platform that currently the company sells tadalafil tablets as agents account for a small share of revenue. Currently, the company is mainly focusing on core advantage products, actively expanding the market of its flagship product Canalin in clinical fields such as thyroid, broadening the generic drug market, actively introducing new products and technologies, etc., and increasing the company's revenue level.
Express News | Laimei Pharmaceutical selects thirteen provincial federated drugs from voriconazole tablets and paclitaxel injections
Laimei Pharmaceutical (300006.SZ): CUD005 injection approved to conduct clinical trials to treat decompensated liver cirrhosis
Laimei Pharmaceutical (300006.SZ) announced that the company participated in the company Sichuan Kangdesai Medical Technology Co., Ltd. (abbreviation “...
Express News | Laimei Pharmaceutical: The participating company obtained the CUD005 injection clinical trial approval notice
Laimei Pharmaceutical (300006.SZ) subsidiary's endoscopic products obtained medical device registration certificate
Zhitong Finance App News, Laimei Pharmaceutical (300006.SZ) issued an announcement. Recently, Hainan Laimei Medical Devices Co., Ltd. (hereinafter referred to as “Laimei Medical Devices”), a holding subsidiary of the company, received two “medical device registration certificates” issued by the Hainan Drug Administration. The products are: “electromechanical endoscopic image processor” and “disposable electronic bronchial imaging catheter”. The single-use electronic bronchial imaging catheter and electronic endoscopic image processor, which obtained the “Medical Device Registration Certificate” this time, is an endoscopic product developed by Laimei Medical Devices. This product can directly observe patient images, which is beneficial
Laimei Pharmaceutical (300006.SZ): net loss of 8.9273 million yuan in 2023
Gelonghui, March 22丨Laimei Pharmaceutical (300006.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 896 million yuan, an increase of 1.24% over the previous year; net profit attributable to shareholders of listed companies was -8.9273 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -59.333 million yuan; and basic earnings per share was -0.0085 yuan.
Express News | The ban on restricted stocks with a market capitalization of 11.182 billion yuan was lifted today. Among them, drones ranked first with a market capitalization of 3.137 billion yuan
Laimei Pharmaceutical (300006.SZ): The ban on 244 million restricted shares will be lifted on March 22
On March 19, Ge Longhui Pharmaceutical (300006.SZ) announced an indicative announcement on the listing and circulation of restricted shares issued to specific targets. The shares that have been lifted are the company's shares issued to specific targets in 2021. The total number of shareholders applying to lift sales restrictions is 3. The number of shares that have been lifted this time is 244 million shares, accounting for 23.08% of the company's total share capital. The listing and circulation date for the shares whose sales restrictions have been lifted is March 22, 2024 (Friday).
Lemei Pharmaceutical (300006.SZ): Obtained the drug registration certificate for omeprazole magnesium enteric tablets (20mg)
Gelonghui, March 19 | Lemei Pharmaceutical (300006.SZ) announced that recently, Chongqing Laimei Pharmaceutical Co., Ltd. received the “Drug Registration Certificate” for 20 mg omeprazole magnesium enteric tablets approved and issued by the State Drug Administration. Omeprazole magnesium enteric tablets are mainly used to treat duodenal ulcers, stomach ulcers and reflux esophagitis; use in combination with antibiotics to treat duodenal ulcers caused by Helicobacter pylori; treat peptic ulcers or gastroduodenal erosions associated with nonsteroidal anti-inflammatory drugs; prevent peptic ulcers, gastroduodenal erosion or indigestion caused by nonsteroidal anti-inflammatory drugs;
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug
China's National Medical Products Administration approved the application of Guangxi Wuzhou Zhongheng Group's (SHA:600252) unit, Chongqing Lummy Pharmaceutical (SHE:300006), to increase the dosage of
Express News | Zhongheng Group: The holding subsidiary received a notice of approval for injectable esomeprazole sodium supplementation
Laimei Pharmaceutical (300006.SZ): As of February 29, 2024, the number of shareholders of the company was 34,301
Gelonghui March 13 | Laimei Pharmaceutical (300006.SZ) said on many investor platforms that as of February 29, 2024, the number of shareholders of the company was 34,301.
Laimei Pharmaceutical (300006.SZ): The core product Canalin has been selling well in recent years
Gelonghui, March 5 | Lemei Pharmaceutical (300006.SZ) said on the investor interactive platform that the company's core product, Canalin, has been selling well in recent years. The product has received clinical expert consensus in various fields such as thyroid, mammary, gastrointestinal, and gynecological tumors. It is highly recognized by academic institutions and the market, and has now become a first-line routine medication for thyroid surgery in China. Currently, the company is continuously expanding and enhancing Canalin's market potential in various fields such as gastrointestinal and breast.
Lummy Pharma Gets Nod to Market Nicorandil
Chongqing Lummy Pharmaceutical (SHE:300006) received approval from China's National Medical Products Administration to market raw drug ingredient Nicorandil, according to a Friday disclosure. The raw
Laimei Pharmaceutical (300006.SZ): Remy Longyu obtained approval notice for marketing application for Nicordil raw materials (specification: 4.00kg/bag, 1 bag/bottle)
Gelonghui, March 1 | Laimei Pharmaceutical (300006.SZ) announced that recently, Chongqing Laimei Longyu Pharmaceutical Co., Ltd. (“Laimei Longyu”), a wholly-owned subsidiary of Chongqing Laimei Pharmaceutical Co., Ltd., received the approval and issuance of Nicodyl (Specification: 4.00kg/bag, 1 bag/bottle) “Notice of Approval of Application for Chemical Ingredients” by the State Drug Administration. Nicordil for injection is mainly used for unstable angina pectoris and acute heart failure, improves coronary microcirculation, can effectively reduce cardiovascular events, and can significantly reduce the risk of acute coronary syndrome. Clinical patients benefit a lot.
Laimei Pharmaceutical (300006.SZ): As of February 20, 2024, the number of shareholders of the company was 34,151
Gelonghui Feb. 26 | Laimei Pharmaceutical (300006.SZ) said on the investor interactive platform that as of February 20, 2024, the number of shareholders of the company was 34,151.
Laimei Pharmaceutical (300006.SZ): Pre-loss of 800,000 yuan to 12.00 million yuan in 2023
Gelonghui, January 30, 丨 Laimei Pharmaceutical (300006.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was RMB 800,000 to RMB 12,000,000, with a loss of RMB 687.091 million for the same period of the previous year; net profit loss after deducting non-recurring profit and loss of RMB 73.0 million to 77.0 million yuan, and a loss of 115.3328 million yuan for the same period last year. During the reporting period, Sichuan Kangdesai Medical Technology Co., Ltd. (hereinafter referred to as “Kangdesai”), the company's former holding subsidiary, implemented equity incentives in the form of capital increases. The company and
Laimei Pharmaceutical (300006.SZ): As of January 10, 2024, the number of shareholders of the company was 34,307
Gelonghui January 15 | Laimei Pharmaceutical (300006.SZ) said on the investor interactive platform that as of January 10, 2024, the number of shareholders of the company was 34,307.
Qiu Yu, the majority shareholder of Laimei Pharmaceutical (300006.SZ), passively reduced his holdings by 0.99% in total, and the share reduction period expires
Laimei Pharmaceutical (300006.SZ) issued an announcement. The company received shareholder Qiu Yu's “On the Passive Reduction Plan for Shares...
Analysis
Price Target
No Data
